Prostate Cancer

Here are the drugs and financial support services available to patients receiving treatment for Prostate Cancer.

The PARP inhibitor Lynparza (olaparib), a type of drug that is usually used for the treatment of women with ovarian cancer, has also been studied in men with prostate cancer. The results of the PROfound clinical trial were recently presented at the 2020 ASCO annual meeting by Antoine Thiery-Vuillemin, MD, PhD, Centre Hospitalier de Besançon, France.

Results of a new study showed that the combination of Cabometyx (cabozantinib) and the immune checkpoint inhibitor Tecentriq (atezolizumab) was safe and effective in men with metastatic (spreading) castration-resistant prostate cancer, the most common type of prostate cancer.

Dennis Golden was an active, fit, 70-year-old when he learned he had prostate cancer. He was surprised to discover that few men know the warning signs and how potentially serious it can be. In response, he formed the National Prostate Cancer Awareness Foundation to educate men about this disease.

Retiree Greg Kelly has a passion and affinity for model building.

Frank dela Rama explains the options available today, the limitations, and possibilities in the future for the diagnosis of prostate cancer.

Oncology navigator Frank dela Rama lists the screening tools available now for diagnosing prostate cancer.

Frank dela Rama talks about some of the stigma and miscommunication surrounding prostate cancer screening and the need for clarity.

Frank dela Rama explains the current recommendations for screening for prostate cancer.